glp-1 milwaukee Join us at the iaedp Chapter for a continuing education event exploring emerging clinical considerations in eating disorder treatment. This 5 CE-credit program will feature a presentation by Dr. Kim Dennis GLP-1s Like Ozempic May Be

Last year, he found himself battling Hodgkin's lymphoma

The drugs have proven to be remarkable cash cows for their manufacturers

Clinical data is lacking

It even appears that it could find future application in the research of depression or cancer

There are a number of these medications currently available, some of which include: Semaglutide injection (Ozempic) Semaglutide injection (Wegovy) Semaglutide tablets (Rybelsus) Dulaglutide (Trulicity) Exenatide (Byetta) Exenatide extended-release (Bydureon) Liraglutide (Victoza) Lixisenatide (Adlyxin) Tirzepatide injection (Mounjaro) Source [1] Global GLP-1 receptor agonist market In 2024, the global GLP-1 receptor agonist market size was valued at an estimated USD 53.46 billion and is projected to reach USD 156.71 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 17.46% between 2025 and 2030